Nodal Station as a Prognostic Factor in Resected Stage IIIA N2 Non-Small Cell Lung Cancer

절제된 IIIA N2 병기 비소세포형 폐암에 있어서 Nodal Station의 의의

  • 김대준 (연세대학교 의과대학 흉부외과학교실) ;
  • 김길동 (연세대학교 의과대학 흉부외과학교실) ;
  • 김치영 (연세대학교 의과대학 흉부외과학교실) ;
  • 정경영 (연세대학교 의과대학 흉부외과학교실)
  • Published : 2003.07.01

Abstract

To clarify the prognostic implication of the location and number of the metastatic mediastinal nodes in resected stage IIIA N2 non-small cell lung cancer. Material and Method: One hundred and seventy-four patients with resected non-small cell lung cancer who eventually proved to have pathologic stage IIIA N2 disease were studied. Patients who received preoperative induction therapy, non-curative operation or defined as operative mortality were excluded from this study. Result: In upper lobe tumors, there was no difference in 5-year survival according to the involvement of lower mediastinal nodes (32.3% vs 25.6%, p=0.86). In lower lobe tumors, no difference was found in 5-year survival according to the involvement of upper mediastinal nodes (25.1% vs 14.1%, p=0.33). There was no significant difference in 5-year survival between patients with or without metastatic subcarinal node (20.9% vs 25.6%, p=0.364). In terms of the number of metastatic mediastinal nodes, 5-year survival was better in single station group (26.3%) than multiple station group (18.3%) (p=0.048). In multiple station N2 group, the patients who received postoperative chemotherapy and radiation therapy had better 5-year survival (34.2%) (p=0.01). Cox's proportional hazards model revealed that the age $\geq$60 (O.R: 1.682, p=.006), multiple station N2 (O.R: 1.503. p=0.021), pneumonectomy (O.R: 1.562, p=0.018), postoperative chemotherapy and radiation therapy (O.R: 0.625, p=0.012) were the factors affecting the postoperative survival. Conclusion: Multiple station N2 disease was the important prognostic factor for postoperative survival in resected stage IIIA N2 non-small cell lung cancer. Postoperative chemotherapy and radiotherapy were thought to improve the survival in case of multiple station N2 disease.

절제된 IIIA N2병기 비소세포형 폐암에 있어서 종격동임파절의 전이 양상에 따른 임상적 특성을 알아보고, 예후에 미치는 영향에 대해 평가해 보고자 하였다. 대상 및 방법: 1991년 1월부터 2000년 12월까지 비소세포형 폐암으로 폐엽절제술 이상의 수술을 받은 환자 중 수술 전 항암 화학요법 또는 방사선 치료를 받은 환자와 수술 사망 환자를 제외한 174명을 대상으로 후향적 연구를 자였다. 결과: 상엽 종양에서 하부 종격동임파절로 전이된 경우 5년 생존율은 32.3%로서,하부 종격동임파절 전이가 없는 환자의 5년 생존율 25.6%와 차이가 없었다(p=0.86). 하엽 종양에서 상부 종격동임파절로 전이된 경우 5년 생존율은 25.1%로, 상부 종격동임파절 전이가 없는 환자의 5년 생존율 14.1%와 비교하여 통계학적인 차이가 없었다(p=.33). 전체 환자 중 subcarinal node로의 전이에 따른 생존율의 비교시 전이 유무에 따른 5년 생존율에 차이가 없었다(20.9% vs 25.6%, p=0.364). 전이된 종격동임파절의 station수에 따른 비교 시 single station군의 5년 생존율은 26.3%로, multiple station군의 18.3%보다 생존율이 유의하게 높았다(p=0.048). Multiple station군에 있어서 수술 후 항암 화학 요법 및 방사선 치료를 병행한 경우 5년 생존율 34.2%로서 생존율의 향상이 있었다(p=0.01). 수술 후 생존에 영향을 미치는 인자로는 연령 $\geq$60세(O.R: 1.682, p=.006), multiple station N2 (O.R: 1.503, p=.021), 전페절제술(O.R: 1.562, p=.018), 수술 후 항암 화학요법 및 방사선 치료(O.R: 0.625, p=.012)등이 있었다. 결론: 절제된 IIIA N2 병기 비소세포형 폐암에 있어서 전이된 종격동임파절 부위의 수(single vs multiple station)가 술 후 생존에 영향을 미치는 중요한 예후 인자였으며, multiple station N2의 경우 수술 후 항암 화학요법 및 방사선 치료를 병행함으로써 생존율을 높일 수 있으리라 생각된다.

Keywords

References

  1. Pearson FG, DeLarue NC, lives R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorae Vase Surg 1982;83:1-11.
  2. Watanabe Y, Shimizu J, Oda M, et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorae Surg 1991;51:253-61.
  3. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases. The Leuven lung Cancer Group. Ann Thorae Surg 1997;63:1441-50.
  4. Martini N, Flehinger 81. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.
  5. Naruke T, Goya T, Tsuehiya R, et al. The importance of surgery to non-small cell lung cancer with ipsilateral mediastinal lymph node metastasis. Ann Thorae Surg 1988;46: 603-10.
  6. Naruke T, Suematsu K. Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorae Cardiovasc Surg 1978;76:832-9.
  7. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoe 1958;53:457-81.
  8. Cox DW. Regression models and life tables. J R Stat Soe 1972;34:187-220.
  9. Takizawa T, Terashima M, Koike T, Akamatsu H, Kurita Y, Yokoyama A. Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small cell lung cancer. J Thorae Cardiovase Surg 1997;113:248-52.
  10. Asamura H, Nakayama H, Kondo H, Tsuehiya R, Naruke T.Lobe-specific extent of systematic lymph node dissection for non-small cell carcinomas according to a retrospective study of metastasis and prognosis. J Thome Cardiovasc Surg 1999; 117: 1102-11.
  11. Ichinose Y, Kato H, Koike T, et al. Completely resected stage lIlA non-small cell lung cancer: The significance of primary tumor location and N2 station. J Thome Cardiovase Surg 2001;122:803-8.
  12. Miller DL, McManus KG, Allen MS, et al. Results of surgical resection of patients with N2 non-small cell lung cancer. Ann Thome Surg 1994;57:1095-1101.
  13. Okada M, Tsubota N, Yoshimura M, et al. Prognosis of completely resected pN2 non-small cell lung carcinomas: What is the significant node that affects survival? J Thome Cardiovase Surg 1999;118:270-5.
  14. Patterson GA, Piazza 0, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorae Surg 1987;43: 155-9.
  15. Kirsh M, Sloan H. Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and locations. Ann Thorae Surg 1982;33:459-6.
  16. Goldstraw P, Mannam G, Kaplan D, et al. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorae Cardiovase Surg 1994;107: 19-28.
  17. NoW He. The spread of carcinoma of the bronchus. London: Lloyd-Luke Ltd 1962;17-44.